Study guide

8.3 Central PN Macronutrient Formulation

Certified Nutrition Support Clinician CNSC

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Nutrition Screening, Dietary Evaluation & Energy Requirements

1.1 Nutrition Screening & Validated Risk Tools 1.2 Dietary History & Nutrient Intake Assessment 1.3 Energy Expenditure Estimation & Indirect Calorimetry

2 Chapter 2: Macronutrients, Micronutrients & Fluid Management

2.1 Protein Requirements & Nitrogen Balance 2.2 Fluid Requirements & Electrolyte Homeostasis 2.3 Essential Vitamins & Trace Elements

3 Chapter 3: Anthropometrics, Physical Exam & Malnutrition Consensus

3.1 Anthropometric Assessment & Body Composition 3.2 Nutrition-Focused Physical Examination (NFPE) 3.3 AND/ASPEN & GLIM Malnutrition Criteria

4 Chapter 4: Pediatric & Specialized Nutrition Assessment

4.1 Pediatric & Neonatal Nutrition Assessment 4.2 Biochemical Assessment, Visceral Proteins & Inflammation

5 Chapter 5: Enteral Nutrition Access & Tube Management

5.1 Enteral Access Modalities & Route Selection 5.2 Tube Placement Verification & Stoma Site Care

6 Chapter 6: Enteral Formulation, Regimen Design & Administration

6.1 Enteral Formula Classification & Selection 6.2 Enteral Delivery Methods & Infusion Schedules 6.3 Enteral Fluid Management & Free Water Requirements

7 Chapter 7: Enteral Complications & Medication Administration

7.1 Enteral Gastrointestinal Complications 7.2 Enteral Metabolic, Mechanical & Pulmonary Complications 7.3 Drug-Nutrient Interactions & Enteral Medication Delivery

8 Chapter 8: Parenteral Nutrition Indications, Access & Formulation Design

8.1 Parenteral Nutrition Indications & Venous Access Routes 8.2 Peripheral Parenteral Nutrition (PPN) Parameters 8.3 Central PN Macronutrient Formulation

9 Chapter 9: Parenteral Additives, Compounding & Physical Stability

9.1 Parenteral Electrolytes, Trace Elements & Vitamins 9.2 Calcium-Phosphate Solubility & Precipitation Risks 9.3 Physical Stability, Total Nutrient Admixtures & Filtration

10 Chapter 10: Parenteral Complications, CLABSI & Organ Toxicities

10.1 Central Line-Associated Bloodstream Infections & Mechanical Risks 10.2 Refeeding Syndrome Pathophysiology & Prevention 10.3 Parenteral Nutrition-Associated Liver Disease & Metabolic Bone Disease

11 Chapter 11: Critical Care, Obesity & Pulmonary Nutrition Support

11.1 Critical Illness, Sepsis & Trauma Nutrition 11.2 Nutrition Support in Obesity & Hypocaloric Feeding 11.3 Pulmonary Failure & Mechanical Ventilation 11.4 Nutrition Support Care Plans, Goals & Therapy Reassessment

12 Chapter 12: Organ Failure: Renal, Hepatic & Gastrointestinal Support

12.1 Acute Kidney Injury & Renal Replacement Therapy 12.2 Cirrhosis, Hepatic Encephalopathy & Acute Pancreatitis 12.3 Short Bowel Syndrome & Intestinal Failure

13 Chapter 13: Oncology, Surgical Care & Intestinal Failure

13.1 Oncology Nutrition & Cancer Cachexia 13.2 Perioperative Nutrition & Enhanced Recovery After Surgery (ERAS) 13.3 Enterocutaneous Fistulas & Severe Malabsorption

14 Chapter 14: Process Management, Compounding Safety & Home Nutrition Support

14.1 PN Order Verification, Compounding Safety & USP Standards 14.2 Home Nutrition Support (HNS) & Care Transitions 14.3 Nutrition Support Policies, Product Shortages & Patient Education

15 Chapter 15: Professional Practice, Ethics & Interdisciplinary Care

15.1 Ethical Principles & Withholding/Withdrawing Artificial Nutrition 15.2 The Interdisciplinary Nutrition Support Team 15.3 Quality Improvement, Malnutrition Documentation & Clinical Standards 15.4 Critical Appraisal of Nutrition Research & Evidence

8.3 Central PN Macronutrient Formulation

Key Takeaways Explain This Topic AI

Dextrose monohydrate provides 3.4 kcal/g (containing one molecule of hydration water) and requires a minimum daily intake of 100 to 150 g/day (~2 g/kg/day) to suppress hepatic gluconeogenesis, prevent starvation ketosis, and spare somatic protein.

Crystalline amino acids yield 4.0 kcal/g; standard balanced solutions are suitable for most patients, while specialized formulations include BCAA-enriched blends for refractory hepatic encephalopathy and cysteine-supplemented blends for neonates.

Intravenous lipid emulsions (IVLE) provide 1.1 kcal/mL (10%), 2.0 kcal/mL (20%), and 3.0 kcal/mL (30%), with 20% formulations preferred over 10% due to a more favorable phospholipid-to-triglyceride ratio that prevents delayed chylomicron clearance.

Essential fatty acid deficiency (EFAD) presents with scaly dermatitis, alopecia, and poor wound healing, diagnosed by a Holman index (triene-to-tetraene ratio / mead acid to arachidonic acid ratio) > 0.2, prevented by supplying 2% to 4% of total energy as linoleic acid and 0.25% to 0.5% as alpha-linolenic acid.

Glucose infusion rate (GIR) must be maintained at ≤ 4 to 5 mg/kg/min in critically ill adults (maximum 7 mg/kg/min in stable adults) to prevent hyperglycemia, osmotic diuresis, hepatic steatosis, and hypercapnic respiratory failure from de novo lipogenesis.

Last updated: October 2026

8.3 Central PN Macronutrient Formulation

Clinical Core: Central parenteral nutrition requires rigorous, individualized formulation of macronutrient substrates—carbohydrates, amino acids, and lipids. Understanding substrate caloric densities, specialized amino acid kinetics, lipid generation profiles, essential fatty acid physiology, and glucose oxidation ceilings is fundamental to avoiding overfeeding toxicities such as hepatic steatosis, hypercapnic respiratory failure, and essential fatty acid deficiency.

Macronutrient Substrates and Caloric Densities

Parenteral macronutrients possess distinct biochemical structures and caloric densities that differ from their enteral counterparts: PARENTERAL MACRONUTRIENT SUBSTRATES

  • 1. DEXTROSE MONOHYDRATE ----> 3.4 kcal/g (Hydrated C6H12O6 · H2O, MW 198.17)
  • 2. CRYSTALLINE AMINO ACIDS -> 4.0 kcal/g (16% Nitrogen: Protein / 6.25 = N)
  • 3. INTRAVENOUS LIPID (IVLE) -> 10% = 1.1 kcal/mL | 20% = 2.0 kcal/mL | 30% = 3.0 kcal/mL
  • 1. Dextrose Monohydrate (Carbohydrate)

Biochemical Structure: In enteral nutrition, dietary starch and anhydrous glucose yield 4.0 kcal/g 4.0\text{ kcal/g} 4.0 kcal/g . In parenteral solutions, dextrose is commercially prepared as dextrose monohydrate ( C 6 H 12 O 6 ⋅ H 2 O C_6H_{12}O_6 \cdot H_2O C 6 ​ H 12 ​ O 6 ​ ⋅ H 2 ​ O , molecular weight 198.17), containing one molecule of water of crystallization. Because this water molecule adds molecular mass without contributing metabolic energy, parenteral dextrose yields exactly 3.4 kcal per gram 3.4\text{ kcal per gram} 3.4 kcal per gram .

Available Stock Concentrations:

  • D 10 W D_{10}W D 10 ​ W ( 10 % = 100 g/L 10\% = 100\text{ g/L} 10% = 100 g/L )
  • D 50 W D_{50}W D 50 ​ W ( 50 % = 500 g/L 50\% = 500\text{ g/L} 50% = 500 g/L )
  • D 70 W D_{70}W D 70 ​ W ( 70 % = 700 g/L 70\% = 700\text{ g/L} 70% = 700 g/L )

Minimum Carbohydrate Requirement: An adult requires a minimum of 100 to 150 g/day 100\text{ to } 150\text{ g/day} 100 to 150 g/day (approximately 2 g/kg/day 2\text{ g/kg/day} 2 g/kg/day ) of carbohydrate to:

Meet the obligate glucose requirements of the human brain ( 100 – 120 g/day 100\text{--}120\text{ g/day} 100 – 120 g/day ), erythrocytes, renal medulla, and healing wounds.

Suppress hepatic gluconeogenesis, preventing rapid endogenous skeletal muscle proteolysis.

Suppress hepatic ketogenesis, preventing starvation ketoacidosis.

2. Crystalline Amino Acids (Protein)

Energy Density & Nitrogen Kinetics: Crystalline amino acids yield 4.0 kcal/g 4.0\text{ kcal/g} 4.0 kcal/g . Nitrogen accounts for approximately 16 % 16\% 16% of amino acid mass by weight, establishing the fundamental nitrogen conversion:

Nitrogen (g) = Amino Acids (g) 6.25 \text{Nitrogen (g)} = \frac{\text{Amino Acids (g)}}{6.25} Nitrogen (g) = 6.25 Amino Acids (g) ​

Stock Concentrations: Standard parenteral amino acid solutions are available in concentrations of 10 % 10\% 10% ( 100 g/L 100\text{ g/L} 100 g/L ), 15 % 15\% 15% ( 150 g/L 150\text{ g/L} 150 g/L ), and 20 % 20\% 20% ( 200 g/L 200\text{ g/L} 200 g/L ).

Formulation Profiles:

Standard Formulations: Balanced mixtures of essential and non-essential amino acids modeled after high-biological-value egg and milk proteins (e.g., Aminosyn, Travasol, Plenamine). Suitable for ≥ 95 % \ge 95\% ≥ 95% of hospitalized adults.

Hepatic Formulations (HepatAmine): Enriched with Branched-Chain Amino Acids (BCAAs: leucine, isoleucine, valine; 35 % – 45 % 35\%\text{--}45\% 35% – 45% ) and depleted of Aromatic Amino Acids (AAAs: phenylalanine, tyrosine, tryptophan) and methionine. Based on the Fischer hypothesis, abnormal serum BCAA-to-AAA ratios allow aromatic amino acids to cross the blood-brain barrier and synthesize "false neurotransmitters" (octopamine, phenylethanolamine), worsening encephalopathy. In modern clinical practice, hepatic formulations are reserved exclusively for patients with severe, chronic hepatic encephalopathy refractory to first-line pharmacotherapy (lactulose and rifaximin). Standard amino acids are preferred in stable cirrhosis.

Renal Formulations (NephrAmine, Aminosyn RF): Formulated with essential amino acids only. Historically developed for non-dialyzed acute kidney injury to promote urea nitrogen recycling. Modern nephrology and critical care guidelines have rendered essential-only amino acid formulations largely obsolete; critically ill patients with AKI on continuous renal replacement therapy (CRRT) require standard balanced amino acid mixtures at high doses ( 1.5 to 2.5 g/kg/day 1.5\text{ to } 2.5\text{ g/kg/day} 1.5 to 2.5 g/kg/day ) to replace dialysate amino acid clearance ( 10 to 15 g/day 10\text{ to } 15\text{ g/day} 10 to 15 g/day ).

Pediatric/Neonatal Formulations (TrophAmine, Premasol): Calibrated for neonatal liver immaturity. Enriched with taurine, histidine, and tyrosine. Crucially, neonatal formulations require the addition of L-cysteine hydrochloride ( 30 to 40 mg 30\text{ to } 40\text{ mg} 30 to 40 mg per gram of amino acids) immediately prior to compounding. Premature neonates have immature hepatic cystathionase activity, making cysteine an essential amino acid. Adding L-cysteine HCl also acidifies the solution pH, significantly enhancing calcium and phosphate solubility .

3. Intravenous Lipid Emulsions (IVLE)

Commercial lipid emulsions provide concentrated, non-protein calories and essential fatty acids:

Emulsion Concentration Total Caloric Density Triglyceride Content Phospholipid Emulsifier Free Glycerol Content

10% IVLE 1.1 kcal/mL 1.1\text{ kcal/mL} 1.1 kcal/mL 100 g/L 100\text{ g/L} 100 g/L 12 g/L 12\text{ g/L} 12 g/L 25 g/L 25\text{ g/L} 25 g/L

20% IVLE 2.0 kcal/mL 2.0\text{ kcal/mL} 2.0 kcal/mL 200 g/L 200\text{ g/L} 200 g/L 12 g/L 12\text{ g/L} 12 g/L 25 g/L 25\text{ g/L} 25 g/L

30% IVLE 3.0 kcal/mL 3.0\text{ kcal/mL} 3.0 kcal/mL 300 g/L 300\text{ g/L} 300 g/L 12 g/L 12\text{ g/L} 12 g/L 16.7 g/L 16.7\text{ g/L} 16.7 g/L

The Phospholipid-to-Triglyceride Ratio Paradox: Notice that 10 % 10\% 10% and 20 % 20\% 20% IVLE both contain the same amount of egg yolk phospholipid emulsifier ( 12 g/L 12\text{ g/L} 12 g/L ). Consequently, a 10 % 10\% 10% lipid emulsion delivers twice the amount of phospholipid per gram of triglyceride compared to a 20 % 20\% 20% emulsion. This excess unesterified phospholipid binds circulating apolipoproteins and forms abnormal vesicular particles called Lipoprotein-X , which inhibits endothelial lipoprotein lipase (LPL). This delays plasma clearance of triglycerides, promoting hypertriglyceridemia and impaired reticuloendothelial clearance. Therefore, 20 % 20\% 20% IVLE is clinically preferred over 10 % 10\% 10% IVLE .

Lipid Generations & Oil Sources EVOLUTION OF INTRAVENOUS LIPID EMULSIONS

  • 1st GENERATION: 100% Soybean Oil (Intralipid)
  • High omega-6 PUFA (54% linoleic acid) -> Pro-inflammatory eicosanoids (PGE2, LTB4)
  • High phytosterols (stigmasterol) -> Impaired bile acid secretion -> PNALD / IFALD
  • MODERN MULTI-OIL: 4-Oil Blend (SMOFlipid)
  • 30% Soybean Oil: Essential linoleic and alpha-linolenic acids
  • 30% MCT (Coconut): Rapid carnitine-independent oxidation, no hepatic accumulation
  • 25% Olive Oil: Rich in oleic acid (MUFA), resistant to lipid peroxidation
  • 15% Fish Oil: Rich in EPA & DHA (omega-3), anti-inflammatory resoltins/protectins
  • Added alpha-tocopherol (vitamin E, ~200 mg/L) | Lower phytosterols | n-6:n-3 ratio ~2.5:1
  • TARGETED THERAPY: 100% Fish Oil (Omegaven)
  • Approved for pediatric patients to reverse Parenteral Nutrition-Associated Cholestasis (PNAC)
  • Clinical Lipid Monitoring and Ceilings

Infusion Rate Limit: Intravenous lipid emulsion should be infused at a rate ≤ 0.11 g/kg/hour \le 0.11\text{ g/kg/hour} ≤ 0.11 g/kg/hour to prevent reticuloendothelial saturation and hypertriglyceridemia.

Dosing Range: General adult dosing is 1.0 to 1.5 g/kg/day 1.0\text{ to } 1.5\text{ g/kg/day} 1.0 to 1.5 g/kg/day (maximum 2.5 g/kg/day 2.5\text{ g/kg/day} 2.5 g/kg/day ). In critical illness, restricting lipid to ≤ 1.0 g/kg/day \le 1.0\text{ g/kg/day} ≤ 1.0 g/kg/day or providing multi-oil formulations mitigates immunosuppression.

Serum Triglyceride Monitoring: Obtain baseline serum triglycerides before initiating IVLE. Withhold or reduce IVLE if serum triglycerides exceed 400 mg/dL 400\text{ mg/dL} 400 mg/dL in adults (or 200 – 250 mg/dL 200\text{--}250\text{ mg/dL} 200 – 250 mg/dL in neonates) to prevent hypertriglyceridemia-induced acute pancreatitis.

Essential Fatty Acid Deficiency (EFAD)

Humans cannot synthesize carbon-carbon double bonds beyond the Δ 9 \Delta^9 Δ 9 position and depend on exogenous provision of two essential fatty acids:

Linoleic Acid (LA, 18:2n-6): Omega-6 polyunsaturated fatty acid.

Alpha-Linolenic Acid (ALA, 18:3n-3): Omega-3 polyunsaturated fatty acid.

Pathophysiology of EFAD

When a patient receives fat-free parenteral nutrition containing continuous high-dose dextrose, continuous insulin secretion suppresses adipose tissue lipolysis. Without exogenous linoleic acid, the intracellular enzyme Δ 6 \Delta^6 Δ 6 -desaturase acts upon the abundant endogenous monounsaturated fatty acid oleic acid (18:1n-9) . Oleic acid is elongated and desaturated into mead acid (5,8,11-eicosatrienoic acid, 20:3n-9) , an abnormal triene: NORMAL STATE (Adequate Linoleate):

Linoleic Acid (18:2n-6) --------> Arachidonic Acid (20:4n-6, TETRAENE)

EFAD STATE (Dextrose suppression + Absence of Linoleate):

Oleic Acid (18:1n-9) -----------> Mead Acid (20:3n-9, TRIENE)

The Holman Index: Biochemical EFAD is diagnosed using the triene-to-tetraene ratio (the ratio of mead acid to arachidonic acid). A triene-to-tetraene ratio > 0.2 > 0.2 > 0.2 confirms biochemical EFAD. Biochemical deficiency can develop within 7 to 14 days 7\text{ to } 14\text{ days} 7 to 14 days in infants and 1 to 3 weeks 1\text{ to } 3\text{ weeks} 1 to 3 weeks in adults receiving fat-free PN.

Clinical Manifestations: Clinical symptoms appear after 2 to 4 weeks: dry, scaly erythematous dermatitis (ichthyosis-like desquamation, particularly in intertriginous areas), generalized alopecia, delayed wound healing, increased capillary fragility, thrombocytopenia, and increased susceptibility to infection.

Prevention Requirements:

Supply 2 % to 4 % 2\%\text{ to } 4\% 2% to 4% of total daily calories as linoleic acid and 0.25 % to 0.5 % 0.25\%\text{ to } 0.5\% 0.25% to 0.5% as alpha-linolenic acid.

This requirement is satisfied by administering 250 to 500 mL 250\text{ to } 500\text{ mL} 250 to 500 mL of 20 % 20\% 20% soybean oil IVLE once or twice weekly , or by incorporating daily multi-oil lipid emulsions ( 1.0 g/kg/day 1.0\text{ g/kg/day} 1.0 g/kg/day ).

Glucose Infusion Rate (GIR)

The Glucose Infusion Rate (GIR) measures the rate at which intravenous carbohydrate is delivered to the circulation, normalized to body weight and time:

GIR (mg/kg/min) = Dextrose (grams) × 1000 1440 × Weight (kg) = Dextrose (grams) × 0.6944 Weight (kg) \text{GIR (mg/kg/min)} = \frac{\text{Dextrose (grams)} \times 1000}{1440 \times \text{Weight (kg)}} = \frac{\text{Dextrose (grams)} \times 0.6944}{\text{Weight (kg)}} GIR (mg/kg/min) = 1440 × Weight (kg) Dextrose (grams) × 1000 ​ = Weight (kg) Dextrose (grams) × 0.6944 ​

Where 1440 1440 1440 is the total minutes in a 24-hour day ( 24 hr × 60 min/hr = 1440 min 24\text{ hr} \times 60\text{ min/hr} = 1440\text{ min} 24 hr × 60 min/hr = 1440 min ). For a cyclic infusion infused over H H H hours:

GIR cyclic = Dextrose (grams) × 1000 60 × H × Weight (kg) \text{GIR}_{\text{cyclic}} = \frac{\text{Dextrose (grams)} \times 1000}{60 \times H \times \text{Weight (kg)}} GIR cyclic ​ = 60 × H × Weight (kg) Dextrose (grams) × 1000 ​

Physiological Oxidation Ceilings

Patient Population Maximum Recommended GIR Clinical Rationale

Critically Ill Adults 4 to 5 mg/kg/min 4\text{ to } 5\text{ mg/kg/min} 4 to 5 mg/kg/min Severe insulin resistance, elevated counterregulatory hormones (epinephrine, cortisol, glucagon); unsuppressed endogenous gluconeogenesis

Stable Inpatient Adults 4 to 7 mg/kg/min 4\text{ to } 7\text{ mg/kg/min} 4 to 7 mg/kg/min Maximum hepatic glucose oxidation capacity in unstressed states (target ≤ 5 mg/kg/min \le 5\text{ mg/kg/min} ≤ 5 mg/kg/min )

Pediatric Patients 8 to 10 mg/kg/min 8\text{ to } 10\text{ mg/kg/min} 8 to 10 mg/kg/min Higher resting metabolic rate and larger brain-to-body weight ratio

Neonates & Preterm Infants 10 to 14 mg/kg/min 10\text{ to } 14\text{ mg/kg/min} 10 to 14 mg/kg/min High cerebral glucose utilization; advanced incrementally from 4 – 6 mg/kg/min 4\text{--}6\text{ mg/kg/min} 4 – 6 mg/kg/min

Consequences of Exceeding Maximum GIR

Administering dextrose beyond maximum physiological oxidation capacity produces severe metabolic toxicities:

Severe Hyperglycemia and Hyperosmolar Complications: Exceeding insulin-mediated transport results in severe hyperglycemia ( > 180 mg/dL > 180\text{ mg/dL} > 180 mg/dL ), glucosuria, osmotic diuresis, dehydration, loss of electrolytes (potassium, phosphate, magnesium), and increased risk of nosocomial infections.

Hepatic Steatosis: When glucose infusion exceeds the liver's oxidative capacity, excess carbohydrate is redirected into de novo lipogenesis , synthesizing palmitate and triglycerides. This leads to acute fat accumulation in hepatocytes (steatosis) and progressive elevation of transaminases and alkaline phosphatase.

Hypercapnia and Respiratory Compromise: De novo lipogenesis has a Respiratory Quotient (RQ) between 1.0 and 1.3 1.0\text{ and } 1.3 1.0 and 1.3 :

RQ = V CO 2 V O 2 \text{RQ} = \frac{V_{\text{CO}_2}}{V_{\text{O}_2}} RQ = V O 2 ​ ​ V CO 2 ​ ​ ​

Converting carbohydrate into fat releases substantial carbon dioxide ( V CO 2 V_{\text{CO}_2} V CO 2 ​ ​ ) relative to oxygen consumed ( V O 2 V_{\text{O}_2} V O 2 ​ ​ ). In mechanically ventilated patients or those with borderline pulmonary reserve (COPD, ARDS), the resulting hypercapnia dramatically increases minute ventilation demands and the work of breathing, precipitating respiratory acidosis and failure to wean from mechanical ventilation.